Gain Therapeutics Inc (GANX) Stock Forecast & Price Target
Gain Therapeutics Inc · NASDAQ
$1.73-0.13 (-6.99%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 4 firms covering Gain Therapeutics Inc, 4 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets span $5.00 to $8.00, a moderate spread. The average target of $6.50 sits 276% above the current $1.73. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.16 next quarter toward $-0.60 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 ratings
Moderate Buy
Strong Buy00%
Buy4100%
Hold00%
Sell00%
Strong Sell00%
Based on 4 analysts giving stock ratings to Gain Therapeutics Inc.
As of Jul, 4 of 4 firms rate GANX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
GANX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.16
Range $-0.21 – $-0.13 · 4 analysts · +5% YoY
Next period, 4 analysts expect Gain Therapeutics Inc to earn $-0.16 a share (range $-0.21 – $-0.13), versus $-0.15 a year earlier. Full-year consensus is $-0.60, growing to $-0.60 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 4 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Gain Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on GANX.
#1
Keay Nakae
Chardan Capital · Rank #130
Buy
$6.00+246.8% to target
Overall win rate
41%
+ Follow
#2
Raghuram Selvaraju
HC Wainwright & Co. · Rank #249
Buy
$8.00+362.4% to target
Overall win rate
37%
+ Follow
#3
Jay Olson
Oppenheimer · Rank #302
Buy
$8.00+362.4% to target
Overall win rate
32%
+ Follow
#4
Jason McCarthy
Maxim Group · Rank #360
Buy
$7.00+304.6% to target
Overall win rate
30%
+ Follow
#5
Thomas Shrader
BTIG
Buy
$5.00+189.0% to target
Coverage
—
+ Follow
GANX stock forecast FAQ
What is GANX's average 12-month price target?+
The 4 analysts with a live target average $6.50 for Gain Therapeutics Inc over the next 12 months, ranging from a $8.00 high to a $5.00 low.
Is GANX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 4 analyst ratings, 4 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for GANX?+
The Street-high target is $8.00 (HC Wainwright & Co.), and the Street-low is $5.00 (BTIG). The average of all 4 active targets is $6.50.
How many Wall Street analysts cover GANX?+
4 analysts have an active rating on Gain Therapeutics Inc, and 4 firms carry a live 12-month price target.
Who is the most accurate analyst covering GANX?+
Among analysts who currently cover GANX, Keay Nakae of Chardan Capital has the strongest overall Quantellect track record (Rank #130). Their current call is Buy with a $6.00 target.
What is Gain Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.16 per share (range $-0.21 – $-0.13) across 4 analysts. Full-year EPS is projected at $-0.60, rising to $-0.60 the following year.
How much revenue is Gain Therapeutics Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading GANX lately?+
As of Jul, 4 of 4 firms rate GANX a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their GANX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
